Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Status:
Active, not recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pazopanib hydrochloride works in treating patients with
advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.